About Novartis
Novartis is a publicly listed company based in Basel (Switzerland) founded in 1996. RD focused on manufacturing of drugs for multiple therapeutic areas. The company has 75,880 employees. Novartis has completed 42 acquisitions, including ARCTOS medical, Admune Therapeutics and Advanced Accelerator Applications. Its chief executive, as recorded, is Vasant Narasimhan. Its website novartis.com draws about 949 thousand monthly visits. Its focus areas include Biopharma Outsourcing, Diversified, Biologics and Diversified Pharmaceuticals. Its legal entity in India is Novartis Comprehensive Leprosy Care Association (U92410MH1994NPL077457).
Company details
Novartis International AG is a Swiss multinational pharmaceutical company. It ranked number one in sales with 57.9 billion US in the worldwide industry in 2013. In July 2015, Novartis had a market cap of around 280 billion making it the largest healthcare company by this metric. The Company specializes in the research, development, manufacturing, and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care, and generic pharmaceuticals. The Company segments include Pharmaceuticals, which researches, develops, manufactures, distributes, and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines; Alcon, which operates through over three franchises Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, manufactures and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances. In 2022, the company recorded annual revenues of 50.95B and a net profit of 7B.
- Indian entity net loss-₹3,490
FY 2024 · -2652% margin
- Indian entity EBITDA-₹3,490
FY 2024 · -2652% margin
- InvestorsHHS
& 1 more
- Employee Count75,880
- Investments & AcquisitionsARCTOS medical
& 41 more
Associated legal entities of Novartis
Novartis operates through Novartis Comprehensive Leprosy Care Association (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Novartis Comprehensive Leprosy Care Association CIN U92410MH1994NPL077457 | Under Liquidation | 31 Mar 1994 | Mumbai, Maharashtra | ₹0.0 Cr | 3 | View details |
Apps and channels of Novartis
its YouTube channel Novartis has 50K subscribers and 30 videos.
Videos from Novartis
The most watched videos on Novartis's YouTube channel, Novartis (50K subscribers). Click a video to play it here.
More on Novartis.
Funding Insights of Novartis
- Total Rounds 1
- Investors Count 1
All 10 funding rounds of Novartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $578,047 | Grant | – | – | |
| Jun 2018 | $595,941 | Grant | – | – | |
| Jul 2017 | Grant | – | – | ||
| May 2017 | $374,139 | Grant | – | – | |
| Mar 2017 | Grant | – | – | ||
| Feb 2017 | Grant | – | – | ||
| Jan 2017 | $84,214 | Grant | – | – | |
| Sep 2016 | $342,115 | Grant | – | – | |
| Mar 2016 | $401,151 | Grant | – | – | |
| Feb 2016 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Novartis
Novartis has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Novartis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Novartis Comprehensive Leprosy Care Association (Novartis)
Novartis Comprehensive Leprosy Care Association is the primary company behind Novartis. The board of Novartis Comprehensive Leprosy Care Association currently have 3 directors; the longest-serving is Sanjeev Shrivastav, appointed in 2019. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjeev Shrivastav DIN 02631846 | Director | 17 Sep 2019 | 7 yrs 1 mo | Novartis Comprehensive Leprosy Care Association |
| Shilpa Shashank Joshi DIN 09775615 | Director | 28 Oct 2022 | 4 yrs | Novartis Comprehensive Leprosy Care Association |
| Kumudini Dinesh Bhalerao DIN 03103318 | IRP/RP/Liquidator | 06 Aug 2024 | 2 yrs 3 mo | Novartis Comprehensive Leprosy Care Association |
People of Novartis
617 people are tracked at Novartis (371 in leadership, 12 in board & advisors, 234 in team); the tracked headcount is 75,880.
| Name | Role | Group |
|---|---|---|
Vasant Narasimhan | CEO | Leadership |
Lauren Silverman | Managing Director | Leadership |
Johanne Dinucci | Region Head, Customer Operations & Patient Services | Leadership |
Anne Marie Johnson | Associate Director, Business Insights & Analytics | Leadership |
Gerry Gettinger | Team Leader/sales Director Alternate Channels | Leadership |
Abhishek Srivastava | Associate Director - PSS Analytics & Effectiveness | Leadership |
Markus Gruber | Head IP Solid Tumors And AAA At Novartis | Leadership |
Anonymous | Chief Strategy & Growth Officer | Leadership |
Sherry Smith | Associate Director - People Partner | Leadership |
rheyan cader | Global Head Of People & Organization, RLT Operations | Leadership |
Bridget Stuart | Director, Translational Medicine Discovery And Profiling | Leadership |
Gwennaelle Monnot | Principal Scientist (lab Head) | Leadership |
Nancy Turner | Director | Leadership |
Jennifer Ntiri | Associate Director - NPS Process & Design Improvement | Leadership |
Karen L. Hale | Chief Legal Officer | Leadership |
Tim Sayegh | Director, Marketing Strategy - Multiple Sclerosis Portfolio | Leadership |
Victor Bulto | President, Innovative Medicines US | Leadership |
John Jameson | Business Unit Sales Director | Leadership |
Tara Conforto | Director | Leadership |
Stephanie Danetz | Director | Leadership |
597 more people are available in the full profile.
Complete people profiles for Novartis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Novartis
Novartis is a publicly listed company on the SIX with ticker symbol NOVN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 May 2000
- Listed onNYSE: NVS
- Listed entityNovartis AG
- Exchange sectorHealth technology
- ISINCH0012005267
- Share price113.48 CHF (+0.11% on the day) · 2026-05-11
- Market capitalisation206,950,609,376.00 CHF
- Price to earnings20.2
- EPS (diluted, trailing year)5.61 CHF
- Dividend yield3.26%
- Volume (last session)403,977
- Analyst consensusNeutral
Financials of Novartis
Figures of Novartis Comprehensive Leprosy Care Association, the primary company behind Novartis, for FY 2024. Net loss was -₹3,490 (-2652% margin). EBITDA was -₹3,490 (-2652% margin). Revenue has grown at a compounded annual rate of -37% over three years and -55% over five years.
- -₹3,490Net loss · -2652% margin
- -₹3,490EBITDA · -2652% margin
- ₹80 LakhPaid-up capital
- -37%Revenue CAGR, 3 years
- -55%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 45.29B CHF | 11.61B CHF | 18.53B CHF |
| 2024 | 44.31B CHF | 10.52B CHF | 18.93B CHF |
| 2023 | 40.83B CHF | 13.34B CHF | 18.10B CHF |
| 2022 | 40.31B CHF | 6.64B CHF | 16.30B CHF |
| 2021 | 47.20B CHF | 21.96B CHF | 15.57B CHF |
Balance sheet, profit and loss, cash flow and ratios of Novartis Comprehensive Leprosy Care Association are on its company page.
Detailed financial statements for Novartis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novartis
Novartis has strategically engaged in corporate development activities, having acquired 42 companies. Notable acquisitions include ARCTOS medical, Admune Therapeutics and Advanced Accelerator Applications.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody drug conjugates are developed for cancer treatment. | myricxbio.com | London, United Kingdom | 2019 | Jul 2026 | $1.5B | |
Antibody-siRNA complexes are developed for cancer treatment. | aviditybiosciences.com | San Diego, United States | 2012 | Oct 2025 | $12B | |
Therapeutics for immune disorders are developed by Tourmaline Bio. | tourmalinebio.com | New York, United States | 2021 | Sep 2025 | •••• | |
Developing microRNA-based therapeutics for oncology, infectious, fibrosis and metabolic diseases. | regulusrx.com | San Diego, United States | 2007 | Apr 2025 | $1.7B | |
Novel anticoagulants for thrombosis treatment are developed. | anthostherapeutics.com | Cambridge, United States | 2019 | Feb 2025 | $3.1B | |
AAV-based gene therapies for muscle diseases are developed. | katetherapeutics.com | San Diego, United States | 2020 | Nov 2024 | $1.1B | |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | marianaoncology.com | Watertown, United States | 2020 | May 2024 | $1B | |
Therapeutic antibodies for cancer and other diseases are developed. | morphosys.com | Planegg, Germany | 1992 | Feb 2024 | $2.9B | |
Antibody-based therapeutics are developed for gastrointestinal diseases. | calypsobiotech.com | 2013 | Jan 2024 | $250M | ||
Therapies for kidney diseases are developed by SanReno. | sanreno.com | Shanghai, China | 2021 | Jan 2024 | •••• |
Complete acquisition details for Novartis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novartis
13 dated milestones of Novartis across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Novartis is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Acquisition Acquires SanReno.
- Acquisition Acquires Calypso Biotech.
- Acquisition Acquires MorphoSys.
- Acquisition Acquires Mariana Oncology.
- Acquisition Acquires Kate Therapeutics.
- Acquisition Acquires Anthos Therapeutics.
- Acquisition Acquires Regulus Therapeutics.
- Acquisition Acquires Tourmaline Bio.
- Acquisition Acquires Avidity Biosciences.
- Acquisition Acquires Myricx Bio.
Web traffic of Novartis
The website of Novartis (novartis.com) receives about 948.8K visits a month and ranks #58,822 among all websites worldwide, #1,571 in Biotechnology and Pharmaceuticals.
- Monthly visits948.8K
▲ 3.8% vs previous month
- Unique visitors457.7K
per month
- Global rank#58,822
among all websites
- Category rank#1,571
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit2.7
- Average visit1 min 27 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with Novartis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| roche.com | 92% | 1.3M | #42,219 | View details | |
| astrazeneca.com | 91% | 1.3M | #48,983 | View details | |
| phrma.org | 88% | 63.3K | #555,565 | View details | |
| sandoz.com | 86% | 195.3K | #232,061 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Novartis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novartis
Complete news archive for Novartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novartis
Novartis was founded in 1996 and raised its 1st funding round 20 years after it was founded.
Novartis is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Vasant Narasimhan is the CEO of Novartis, as recorded in our data.
Novartis has 75,880 employees.
Annual revenue of Novartis is $57.14B as on Dec 31, 2025.
Novartis International AG is a Swiss multinational pharmaceutical company. It ranked number one in sales with 57.9 billion US in the worldwide industry in 2013. In July 2015, Novartis had a market cap of around 280 billion making it the largest healthcare company by this metric. The Company specializes in the research, development, manufacturing, and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care, and generic pharmaceuticals. The Company segments include Pharmaceuticals, which researches, develops, manufactures, distributes, and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines; Alcon, which operates through over three franchises Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, manufactures and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances. In 2022, the company recorded annual revenues of 50.95B and a net profit of 7B.
Yes, Novartis is publicly traded on SIX under the ticker symbol NOVN.
Novartis has made 42 acquisitions, including ARCTOS medical, Admune Therapeutics, and Advanced Accelerator Applications.
Novartis has 2 investors. Key investors include HHS, and European Union.
Novartis operates through Novartis Comprehensive Leprosy Care Association.
The legal entities of Novartis currently have 3 directors, including Shilpa Shashank Joshi, Kumudini Dinesh Bhalerao, Sanjeev Shrivastav.
The website of Novartis receives about 949 thousand visits a month and ranks #58,822 among all websites worldwide.